

Ref: FOI/GS/ID 9184

**Please reply to:**  
FOI Administrator  
Trust Management  
Maidstone Hospital  
Hermitage Lane  
Maidstone, Kent  
ME16 9QQ  
Email: [mtw-tr.foiadmin@nhs.net](mailto:mtw-tr.foiadmin@nhs.net)  
[www.mtw.nhs.uk](http://www.mtw.nhs.uk)

25 June 2024

## Freedom of Information Act 2000

I am writing in response to your request for information made under the Freedom of Information Act 2000 in relation to Lung cancer.

*You asked: All questions are shown as received by the Trust.*

*Q1. How many non-small cell lung cancer (NSCLC) patients were treated in the past 3 months with:*

- a. *ALK Inhibitors (Alectinib, Brigatinib, Ceritinib, Crizotinib, Lorlatinib)*
- b. *Amivantamab*
- c. *Atezolizumab Monotherapy*
- d. *Atezolizumab + Bevacizumab + Carboplatin + Paclitaxel*
- e. *Dabrafenib + Trametinib*
- f. *Docetaxel monotherapy or in combination with Carboplatin/Cisplatin*
- g. *Durvalumab*
- h. *Gemcitabine*
- i. *Nitedanib + Docetaxel*
- j. *Nivolumab*
- k. *Osimertinib*
- l. *Other EGFR Inhibitors (Afatinib, Erlotinib, Gefitinib, Dacomitinib, Mobocertinib)*
- m. *Paclitaxel*
- n. *Pembrolizumab Monotherapy*
- o. *Pembrolizumab + Paclitaxel + Platinum (Carboplatin/Cisplatin)*
- p. *Pembrolizumab + Pemetrexed + Platinum (Carboplatin/Cisplatin)*
- q. *Pemetrexed + Platinum (Carboplatin/Cisplatin)*
- r. *RET Inhibitors (Pralsetinib, Selpercatinib)*
- s. *Sotorasib*
- t. *Tepotinib*
- u. *Vinorelbine monotherapy or in combination with Carboplatin/Cisplatin*
- v. *Other active systemic anti-cancer therapy*
- w. *Palliative care only*

Q2. How many patients were treated for Squamous non-small cell lung cancer (Sq NSCLC) ONLY in the past 3 months with:

- a. Atezolizumab monotherapy
- b. Durvalumab
- c. Gemcitabine
- d. Nivolumab
- e. Osimertinib
- f. Pembrolizumab (Keytruda) Mono
- g. Pembrolizumab + Paclitaxel + Platinum (Carboplatin/Cisplatin)
- h. Paclitaxel
- i. Vinorelbine monotherapy or in combination with Carboplatin/Cisplatin
- j. Other active systemic anti-cancer therapy (SACT)
- k. Palliative care only

Trust response:

Q1	
a	10
b	0
c	3
d	2
e	5
f	0
g	2
h	0
i	1
j	2
k	30
l	2
m	0
n	16
o	4
p	16
q	5
r	1
s	2
t	2
u	9
v	10
w	1

Q2	
a	0
b	0
c	0
d	0
e	0
f	0
g	3
h	0
i	2
j	3
k	0